Italy’s antitrust authority has launched an investigation against eight pharma companies, including Novartis and Roche, over suspicion they may have colluded to delay the
The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi
President Joe Biden’s budget proposal for fiscal 2025 includes a proposal that would allow pharmacy substitution of biosimilar drugs for the reference product, even if the
Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US
For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat
Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in